Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis

Journal of the American Society of Nephrology

Volumn 22, Issue 7, 2011, Pages 1189-1199

  Rüster, Christiane ^a   Wolf, Gunter ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; CONNECTIVE TISSUE GROWTH FACTOR; CONNECTIVE TISSUE GROWTH FACTOR BETA; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN; ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RHO KINASE; SMAD2 PROTEIN; SMAD3 PROTEIN; THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; CELL ADHESION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROGENESIS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GLOMERULOSCLEROSIS; HUMAN; HYPOXIA; INTRACELLULAR SIGNALING; KIDNEY FIBROSIS; KIDNEY TUBULE CELL; KIDNEY TUBULE EPITHELIUM; MACULA DENSA; MORPHOGENESIS; NEPHRITIS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY; SIGNAL TRANSDUCTION; TRANSACTIVATION;

EID: 79960112806     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2010040384     Document Type: Short Survey

References (146)

1. Harris RC, Neilson EG: Toward a unified theory of renal progression. Annu Rev Med 57: 365-380, 2006 (Pubitemid 43261996)
2. Perico N, Benigni A, Remuzzi G: Present and future drug treatments for chronic kidney diseases: Evolving targets in renoprotection. Nat Rev Drug Discov 7: 936-953, 2008
3. Ruster C, Wolf G: Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 17: 2985-2991, 2006 (Pubitemid 44707758)
4. Kanno Y, Takenaka T, Nakamura T, Suzuki H: Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors. Clin J Am Soc Nephrol 1: 730-737, 2006
5. Kunz R, Friedrich C, Wolbers M, Mann JF: Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148: 30-48, 2008 (Pubitemid 351688350)
6. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
7. Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, Tang AW, Wong TY, Yung CY, Yung JC, Yu AW, Szeto CC: Hong Kong study using valsartan in IgA nephropathy (HKVIN): A double-blind, randomized, placebo-controlled study. Am J Kidney Dis 47: 751-760, 2006
8. Dilauro M, Zimpelmann J, Robertson SJ, Genest D, Burns KD: The effect of ACE2 and angiotensin-(1-7) in a mouse model of early chronic kidney disease. Am J Physiol Renal Physiol 298: F1523-F1532, 2010
9. Wenzel U: Aldosterone and progression of renal disease. Curr Opin Nephrol Hypertens 17: 44-50, 2008
10. Wolf G: Novel aspects of the renin-angiotensin-aldosterone-system. Front Biosci 13: 4993-5005, 2008
11. Remuzzi G, Cattaneo D, Perico N: The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol 19: 1459-1462, 2008
12. Nguyen G, Muller DN: The biology of the (pro)renin receptor. J Am Soc Nephrol 21: 18-23, 2010
13. Chen L, Kim SM, Eisner C, Oppermann M, Huang Y, Mizel D, Li L, Chen M, Lopez ML, Weinstein LS, Gomez RA, Schnermann J, Briggs JP: Stimulation of renin secretion by angiotensin II blockade is Gsalpha-dependent. J Am Soc Nephrol 21: 986-992, 2010
14. Wolf G, Butzmann U, Wenzel UO: The renin-angiotensin system and progression of renal disease: From hemodynamics to cell biology. Nephron Physiol 93: P3-P13, 2003 (Pubitemid 37499910)
15. Oppermann M, Gess B, Schweda F, Castrop H: Atrap deficiency increases arterial blood pressure and plasma volume. J Am Soc Nephrol 21: 468-477, 2010
16. Klahr S, Ishidoya S, Morrissey J: Role of angiotensin II in the tubulointerstitial fibrosis of obstructive nephropathy. Am J Kidney Dis 26: 141-146, 1995
17. Mezzano SA, Ruiz-Ortega M, Egido J: Angiotensin II and renal fibrosis. Hypertension 38: 635-638, 2001
18. Wolf G, Killen PD, Neilson EG: Intracellular signaling of transcription and secretion of type IV collagen after angiotensin II-induced cellular hypertrophy in cultured proximal tubular cells. Cell Regul 2: 219-227, 1991
19. Wolf G, Neilson EG: Angiotensin II induces cellular hypertrophy in cultured murine proximal tubular cells. Am J Physiol 259: F768-F777, 1990 (Pubitemid 20385693)
20. Eddy AA, Neilson EG: Chronic kidney disease progression. J Am Soc Nephrol 17: 2964-2966, 2006 (Pubitemid 44707755)
21. Kimura K, Iwano M: [Molecular mechanisms of tissue fibrosis]. Nihon Rinsho Meneki Gakkai Kaishi 32: 160-167, 2009
22. Zeisberg M, Neilson EG: Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 21: 1819-1834, 2010
23. Macconi D: Targeting the renin angiotensin system for remission/regression of chronic kidney disease. Histol Histopathol 25: 655-668, 2010
24. Wolf G: Link between angiotensin II and TGF-beta in the kidney. Miner Electrolyte Metab 24: 174-180, 1998
25. Wolf G, Neilson EG: From converting enzyme inhibition to angiotensin II receptor blockade: New insight on angiotensin II receptor subtypes in the kidney. Exp Nephrol 4[Suppl 1]: 8-19, 1996 (Pubitemid 26421851)
26. Arai M, Wada A, Isaka Y, Akagi Y, Sugiura T, Miyazaki M, Moriyama T, Kaneda Y, Naruse K, Naruse M, et al.: In vivo transfection of genes for renin and angiotensinogen into the glomerular cells induced phenotypic change of the mesangial cells and glomerular sclerosis. Biochem Biophys Res Commun 206: 525-532, 1995
27. Dussaule JC, Tharaux PL, Boffa JJ, Fakhouri F, Ardaillou R, Chatziantoniou C: Mechanisms mediating the renal profibrotic actions of vasoactive peptides in transgenic mice. J Am Soc Nephrol 11[Suppl 16]: S124-S128, 2000
28. Smith AI, Turner AJ: What's new in the renin-angiotensin system? Cell Mol Life Sci 61: 2675-2676, 2004 (Pubitemid 40022427)
29. Ruiz-Ortega M, Egido J: Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney Int 52: 1497-1510, 1997
30. Pohlers D, Brenmoehl J, Loffler I, Muller CK, Leipner C, Schultze-Mosgau S, Stallmach A, Kinne RW, Wolf G: TGF-beta and fibrosis in different organs - Molecular pathway imprints. Biochim Biophys Acta 1792: 746-756, 2009
31. Wolf G: Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int 70: 1914-1919, 2006
32. Rosenbloom J, Castro SV, Jimenez SA: Narrative review: Fibrotic diseases: Cellular and molecular mechanisms and novel therapies. Ann Intern Med 152: 159-166, 2010
33. Sharma K, Ziyadeh FN: The emerging role of transforming growth factor-beta in kidney diseases. Am J Physiol 266: F829-F842, 1994
34. Wolf G, Mueller E, Stahl RA, Ziyadeh FN: Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest 92: 1366-1372, 1993 (Pubitemid 23273912)
35. Wolf G, Ziyadeh FN, Stahl RA: Angiotensin II stimulates expression of transforming growth factor beta receptor type II in cultured mouse proximal tubular cells. J Mol Med 77: 556-564, 1999 (Pubitemid 29426313)
36. Wolf G, Ziyadeh FN, Zahner G, Stahl RA: Angiotensin II-stimulated expression of transforming growth factor beta in renal proximal tubular cells: Attenuation after stable transfection with the c-mas oncogene. Kidney Int 48: 1818-1827, 1995
37. Weigert C, Brodbeck K, Klopfer K, Haring HU, Schleicher ED: Angiotensin II induces human TGF-beta 1 promoter activation: Similarity to hyperglycaemia. Diabetologia 45: 890-898, 2002
38. Zhou Y, Poczatek MH, Berecek KH, Murphy-Ullrich JE: Thrombospondin 1 mediates angiotensin II induction of TGF-beta activation by cardiac and renal cells under both high and low glucose conditions. Biochem Biophys Res Commun 339: 633-641, 2006 (Pubitemid 41739714)
39. Naito T, Masaki T, Nikolic-Paterson DJ, Tanji C, Yorioka N, Kohno N: Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: A mechanism for activation of latent TGF-beta1. Am J Physiol Renal Physiol 286: F278-F287, 2004 (Pubitemid 38141671)
40. Wolf G, Schneider A, Helmchen U, Stahl RA: AT1-receptor antagonists abolish glomerular MCP-1 expression in a model of mesangial proliferative glomerulonephritis. Exp Nephrol 6: 112-120, 1998 (Pubitemid 28140992)
41. Schneider A, Panzer U, Zahner G, Wenzel U, Wolf G, Thaiss F, Helmchen U, Stahl RA: Monocyte chemoattractant protein-1 mediates collagen deposition in experimental glomerulonephritis by transforming growth factor-beta. Kidney Int 56: 135-144, 1999 (Pubitemid 29300528)
42. Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 93: 2431-2437, 1994 (Pubitemid 24177156)
43. Wolf G, Zahner G, Schroeder R, Stahl RA: Transforming growth factor beta mediates the angiotensin-II-induced stimulation of collagen type IV synthesis in cultured murine proximal tubular cells. Nephrol Dial Transplant 11: 263-269, 1996 (Pubitemid 26063069)
44. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG: Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 110: 341-350, 2002 (Pubitemid 34847966)
45. Sanchez-Lopez E, Rodrigues Diez R, Rodriguez Vita J, Rayego Mateos S, Rodrigues Diez RR, Rodriguez Garcia E, Lavoz Barria C, Mezzano S, Egido J, Ortiz A, Ruiz-Ortega M, Selgas R: [Connective tissue growth factor (CTGF): A key factor in the onset and progression of kidney damage]. Nefrologia 29: 382-391, 2009
46. Wolf G: Angiotensin II as a mediator of tubulointerstitial injury. Nephrol Dial Transplant 15[Suppl 6]: 61-63, 2000
47. Wolf G, Haberstroh U, Neilson EG: Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol 140: 95-107, 1992
48. Kalluri R, Neilson EG: Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112: 1776-1784, 2003 (Pubitemid 38063698)
49. Neilson EG: Mechanisms of disease: Fibroblasts - A new look at an old problem. Nat Clin Pract Nephrol 2: 101-108, 2006
50. Zeisberg M, Neilson EG: Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 119: 1429-1437, 2009
51. Liu Y: New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 21: 212-222, 2010
52. Chen L, Liu BC, Zhang XL, Zhang JD, Liu H, Li MX: Influence of connective tissue growth factor antisense oligonucleotide on angiotensin II-induced epithelial mesenchymal transition in HK2 cells. Acta Pharmacol Sin 27: 1029-1036, 2006 (Pubitemid 44127912)
53. Chen S, Lee JS, Iglesias-de la Cruz MC, Wang A, Izquierdo-Lahuerta A, Gandhi NK, Danesh FR, Wolf G, Ziyadeh FN: Angiotensin II stimulates alpha3(IV) collagen production in mouse podocytes via TGF-beta and VEGF signalling: Implications for diabetic glomerulopathy. Nephrol Dial Transplant 20: 1320-1328, 2005 (Pubitemid 41430605)
54. Rodrigues-Diez R, Carvajal-Gonzalez G, Sanchez-Lopez E, Rodriguez-Vita J, Rodrigues Diez R, Selgas R, Ortiz A, Egido J, Mezzano S, Ruiz-Ortega M: Pharmacological modulation of epithelial mesenchymal transition caused by angiotensin II. Role of ROCK and MAPK pathways. Pharm Res 25: 2447-2461, 2008
55. Saad S, Stanners SR, Yong R, Tang O, Pollock CA: Notch mediated epithelial to mesenchymal transformation is associated with increased expression of the Snail transcription factor. Int J Biochem Cell Biol 42: 1115-1122, 2010
56. Unger T, Sandmann S: Angiotensin receptor blocker selectivity at the AT1- and AT2-receptors: Conceptual and clinical effects. J Renin Angiotensin Aldosterone Syst 1: S6-S9, 2000
57. Peti-Peterdi J, Harris RC: Macula densa sensing and signaling mechanisms of renin release. J Am Soc Nephrol 21: 1093-1096, 2010
58. Razga Z, Nyengaard JR: The effect of angiotensin II on the number of macula densa cells through the AT1 receptor. Nephron Physiol 112: 37-43, 2009
59. Bae EH, Kim IJ, Park JW, Ma SK, Choi KC, Lee JU, Kim SW: Altered regulation of renin-angiotensin, endothelin and natriuretic peptide systems in rat kidney with chronic unilateral ureteral obstruction. Urol Int 79: 170-176, 2007 (Pubitemid 47402745)
60. Dworkin LD, Gong R, Tolbert E, Centracchio J, Yano N, Zanabli AR, Esparza A, Rifai A: Hepatocyte growth factor ameliorates progression of interstitial fibrosis in rats with established renal injury. Kidney Int 65: 409-419, 2004 (Pubitemid 38130635)
61. Yang J, Liu Y: Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. J Am Soc Nephrol 13: 96-107, 2002 (Pubitemid 34042016)
62. Matsumoto K, Morishita R, Tomita N, Moriguchi A, Komai N, Aoki M, Nakamura T, Higaki J, Ogihara T: Improvement of endothelial dysfunction by angiotensin II blockade accompanied by induction of vascular hepatocyte growth factor system in diabetic spontaneously hypertensive rats. Heart Vessels 18: 18-25, 2003 (Pubitemid 36442902)
63. Mezzano S, Droguett A, Burgos ME, Aros C, Ardiles L, Flores C, Carpio D, Carvajal G, Ruiz-Ortega M, Egido J: Expression of gremlin, a bone morphogenetic protein antagonist, in glomerular crescents of pauci-immune glomerulonephritis. Nephrol Dial Transplant 22: 1882-1890, 2007
64. Wang W, Huang XR, Canlas E, Oka K, Truong LD, Deng C, Bhowmick NA, Ju W, Bottinger EP, Lan HY: Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ Res 98: 1032-1039, 2006
65. Wolf G, Ziyadeh FN: Transforming growth factor beta and diabetic nephropathy. J Organ Dysfunct 5: 130-139, 2009
66. Deelman L, Sharma K: Mechanisms of kidney fibrosis and the role of antifibrotic therapies. Curr Opin Nephrol Hypertens 18: 85-90, 2009
67. Grainger DJ: Transforming growth factor beta and atherosclerosis: So far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol 24: 399-404, 2004
68. Gupta S, Clarkson MR, Duggan J, Brady HR: Connective tissue growth factor: Potential role in glomerulosclerosis and tubulo-interstitial fibrosis. Kidney Int 58: 1389-1399, 2000
69. Grotendorst GR: Connective tissue growth factor: A mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev 8: 171-179, 1997
70. Huang S, Liu F, Sha Z, Fu P, Yang Y, Xu Y, Zhou H: Effect of high glucose, angiotensin II and receptor antagonist Losartan on the expression of connective tissue growth factor in cultured mesangial cells. Chin Med J (Engl) 116: 554-557, 2003
71. Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ, Goldschmeding R: Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 53: 853-861, 1998 (Pubitemid 28155657)
72. Lau LF, Lam SC: The CCN family of angiogenic regulators: The integrin connection. Exp Cell Res 248: 44-57, 1999 (Pubitemid 29393928)
73. Li JH, Zhu HJ, Huang XR, Lai KN, Johnson RJ, Lan HY: Smad7 inhibits fibrotic effect of TGF-beta on renal tubular epithelial cells by blocking Smad2 activation. J Am Soc Nephrol 13: 1464-1472, 2002 (Pubitemid 34579235)
74. Liu BC, Sun J, Chen Q, Ma KL, Ruan XZ, Phillips AO: Role of connective tissue growth factor in mediating hypertrophy of human proximal tubular cells induced by angiotensin II. Am J Nephrol 23: 429-437, 2003 (Pubitemid 37465106)
75. Massague J, Chen YG: Controlling TGF-beta signaling. Genes Dev 14: 627-644, 2000
76. Oemar BS, Luscher TF: Connective tissue growth factor. Friend or foe? Arterioscler Thromb Vasc Biol 17: 1483-1489, 1997 (Pubitemid 27387766)
77. Shimo T, Nakanishi T, Nishida T, Asano M, Kanyama M, Kuboki T, Tamatani T, Tezuka K, Takemura M, Matsumura T, Takigawa M: Connective tissue growth factor induces the proliferation, migration, and tube formation of vascular endothelial cells in vitro, and angiogenesis in vivo. J Biochem 126: 137-145, 1999 (Pubitemid 29355403)
78. Yang F, Chung AC, Huang XR, Lan HY: Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent Smad pathways: The role of Smad3. Hypertension 54: 877-884, 2009
79. Lan HY, Mu W, Tomita N, Huang XR, Li JH, Zhu HJ, Morishita R, Johnson RJ: Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol 14: 1535-1548, 2003 (Pubitemid 36687055)
80. Chen R, Huang C, Morinelli TA, Trojanowska M, Paul RV: Blockade of the effects of TGF-beta1 on mesangial cells by overexpression of Smad7. J Am Soc Nephrol 13: 887-893, 2002 (Pubitemid 34274084)
81. Rodriguez-Vita J, Sanchez-Lopez E, Esteban V, Ruperez M, Egido J, Ruiz-Ortega M: Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation 111: 2509-2517, 2005 (Pubitemid 40696140)
82. Finckenberg P, Inkinen K, Ahonen J, Merasto S, Louhelainen M, Vapaatalo H, Muller D, Ganten D, Luft F, Mervaala E: Angiotensin II induces connective tissue growth factor gene expression via calcineurin-dependent pathways. Am J Pathol 163: 355-366, 2003 (Pubitemid 36759620)
83. Hussain A, Wyatt AW, Wang K, Bhandaru M, Biswas R, Avram D, Foller M, Rexhepaj R, Friedrich B, Ullrich S, Muller G, Kuhl D, Risler T, Lang F: SGK1-dependent upregulation of connective tissue growth factor by angiotensin II. Kidney Blood Press Res 31: 80-86, 2008 (Pubitemid 351630064)
84. Gagliardini E, Corna D, Zoja C, Sangalli F, Carrara F, Rossi M, Conti S, Rottoli D, Longaretti L, Remuzzi A, Remuzzi G, Benigni A: Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. Am J Physiol Renal Physiol 297: F1448-F1456, 2009
85. Kanda T, Wakino S, Hayashi K, Homma K, Ozawa Y, Saruta T: Effect of fasudil on Rhokinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats. Kidney Int 64: 2009-2019, 2003
86. Kataoka C, Egashira K, Inoue S, Takemoto M, Ni W, Koyanagi M, Kitamoto S, Usui M, Kaibuchi K, Shimokawa H, Takeshita A: Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 39: 245-250, 2002 (Pubitemid 34165223)
87. Lin SL, Chen RH, Chen YM, Chiang WC, Lai CF, Wu KD, Tsai TJ: Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. J Am Soc Nephrol 16: 2702-2713, 2005
88. Sanchez-Lopez E, Lopez AF, Esteban V, Yague S, Egido J, Ruiz-Ortega M, Alvarez- Arroyo MV: Angiotensin II regulates vascular endothelial growth factor via hypoxiainducible factor-1alpha induction and redox mechanisms in the kidney. Antioxid Redox Signal 7: 1275-1284, 2005 (Pubitemid 41232525)
89. Seccia TM, Maniero C, Belloni AS, Guidolin D, Pothen P, Pessina AC, Rossi GP: Role of angiotensin II, endothelin-1 and L-type calcium channel in the development of glomerular, tubulointerstitial and perivascular fibrosis. J Hypertens 26: 2022-2029, 2008
90. Nagatoya K, Moriyama T, Kawada N, Takeji M, Oseto S, Murozono T, Ando A, Imai E, Hori M: Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int 61: 1684-1695, 2002 (Pubitemid 34437922)
91. Sanchez-Lopez E, Rodriguez-Vita J, Cartier C, Ruperez M, Esteban V, Carvajal G, Rodrigues-Diez R, Plaza JJ, Egido J, Ruiz-Ortega M: Inhibitory effect of interleukin-1beta on angiotensin II-induced connective tissue growth factor and type IV collagen production in cultured mesangial cells. Am J Physiol Renal Physiol 294: F149-F160, 2008
92. Daniels D, Yee DK, Fluharty SJ: Angiotensin II receptor signalling. Exp Physiol 92: 523-527, 2007 (Pubitemid 46608412)
93. Priante G, Musacchio E, Valvason C, Baggio B: EPA and DHA suppress AngII- and arachidonic acid-induced expression of profibrotic genes in human mesangial cells. J Nephrol 22: 137-143, 2009
94. Hu C, Kang BY, Megyesi J, Kaushal GP, Safirstein RL, Mehta JL: Deletion of LOX-1 attenuates renal injury following angiotensin II infusion. Kidney Int 76: 521-527, 2009
95. Burns WC, Twigg SM, Forbes JM, Pete J, Tikellis C, Thallas-Bonke V, Thomas MC, Cooper ME, Kantharidis P: Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: Implications for diabetic renal disease. J Am Soc Nephrol 17: 2484-2494, 2006 (Pubitemid 44300964)
96. Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD, Eguchi S: Angiotensin II signal transduction through the AT1 receptor: Novel insights into mechanisms and pathophysiology. Clin Sci (Lond) 112: 417-428, 2007
97. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, Egido J: Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 10: 321-329, 2001 (Pubitemid 32424019)
98. Sakai N, Wada T, Matsushima K, Bucala R, Iwai M, Horiuchi M, Kaneko S: The reninangiotensin system contributes to renal fibrosis through regulation of fibrocytes. J Hypertens 26: 780-790, 2008 (Pubitemid 351354927)
99. Wenzel UO, Krebs C, Benndorf R: The angiotensin II type 2 receptor in renal disease. J Renin Angiotensin Aldosterone Syst 11: 37-41, 2010
100. Gelosa P, Pignieri A, Fandriks L, de Gasparo M, Hallberg A, Banfi C, Castiglioni L, Turolo L, Guerrini U, Tremoli E, Sironi L: Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: Focus on renal damage. J Hypertens 27: 2444-2451, 2009
101. Sanz AB, Sanchez-Nino MD, Ramos AM, Moreno JA, Santamaria B, Ruiz-Ortega M, Egido J, Ortiz A: NF-kappaB in renal inflammation. J Am Soc Nephrol 21: 1254-1262, 2010
102. Ruperez M, Sanchez-Lopez E, Blanco-Colio LM, Esteban V, Rodriguez-Vita J, Plaza JJ, Egido J, Ruiz-Ortega M: The Rho-kinase pathway regulates angiotensin II-induced renal damage. Kidney Int Suppl 68: S39-S45, 2005
103. Satoh S, Yamaguchi T, Hitomi A, Sato N, Shiraiwa K, Ikegaki I, Asano T, Shimokawa H: Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction. Eur J Pharmacol 455: 169-174, 2002 (Pubitemid 35351611)
104. Teraishi K, Kurata H, Nakajima A, Takaoka M, Matsumura Y: Preventive effect of Y-27632, a selective Rho-kinase inhibitor, on ischemia/reperfusion- induced acute renal failure in rats. Eur J Pharmacol 505: 205-211, 2004 (Pubitemid 39535693)
105. Carvajal G, Rodriguez-Vita J, Rodrigues-Diez R, Sanchez-Lopez E, Ruperez M, Cartier C, Esteban V, Ortiz A, Egido J, Mezzano SA, Ruiz-Ortega M: Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation. Kidney Int 74: 585-595, 2008
106. Ruster C, Bondeva T, Franke S, Tanaka N, Yamamoto H, Wolf G: Angiotensin II upregulates RAGE expression on podocytes: Role of AT2 receptors. Am J Nephrol 29: 538-550, 2009
107. Okada H, Watanabe Y, Inoue T, Kobayashi T, Kikuta T, Kanno Y, Ban S, Suzuki H: Angiotensin II type 1 receptor blockade attenuates renal fibrogenesis in an immune-mediated nephritic kidney through counter-activation of angiotensin II type 2 receptor. Biochem Biophys Res Commun 314: 403-408, 2004 (Pubitemid 38084731)
108. Stoll M, Unger T: Angiotensin and its AT2 receptor: New insights into an old system. Regul Pept 99: 175-182, 2001 (Pubitemid 32522545)
109. Carey RM: Update on the role of the AT2 receptor. Curr Opin Nephrol Hypertens 14: 67-71, 2005
110. Esteban V, Lorenzo O, Ruperez M, Suzuki Y, Mezzano S, Blanco J, Kretzler M, Sugaya T, Egido J, Ruiz-Ortega M: Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol 15: 1514-1529, 2004 (Pubitemid 38679676)
111. Wolf G: "The road not taken": Role of angiotensin II type 2 receptor in pathophysiology. Nephrol Dial Transplant 17: 195-198, 2002
112. Wolf G, Wenzel U, Burns KD, Harris RC, Stahl RA, Thaiss F: Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors. Kidney Int 61: 1986-1995, 2002
113. Wolf G, Ziyadeh FN, Thaiss F, Tomaszewski J, Caron RJ, Wenzel U, Zahner G, Helmchen U, Stahl RA: Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor. J Clin Invest 100: 1047-1058, 1997 (Pubitemid 27386288)
114. Fan YY, Nishiyama A, Fujisawa Y, Kobori H, Nakano D, Matsuura J, Hase N, Hitomi H, Kiyomoto H, Urata H, Kohno M: Contribution of chymase-dependent angiotensin II formation to the progression of tubulointerstitial fibrosis in obstructed kidneys in hamsters. J Pharmacol Sci 111: 82-90, 2009
115. Eddy AA, Fogo AB: Plasminogen activator inhibitor-1 in chronic kidney disease: Evidence and mechanisms of action. J Am Soc Nephrol 17: 2999-3012, 2006 (Pubitemid 44707760)
116. Cohen DL, Townsend RR: Is there added value to adding ARB to ACE inhibitors in the management of CKD? J Am Soc Nephrol 20: 1666-1668, 2009
117. Zhang Y, Kong J, Deb DK, Chang A, Li YC: Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. J Am Soc Nephrol 21, 966-973, 2010
118. Panzer U, Thaiss F, Zahner G, Barth P, Reszka M, Reinking RR, Wolf G, Helmchen U, Stahl RA: Monocyte chemoattractant protein-1 and osteopontin differentially regulate monocytes recruitment in experimental glomerulonephritis. Kidney Int 59: 1762-1769, 2001 (Pubitemid 32336790)
119. Wolak T, Kim H, Ren Y, Kim J, Vaziri ND, Nicholas SB: Osteopontin modulates angiotensin II-induced inflammation, oxidative stress, and fibrosis of the kidney. Kidney Int 76: 32-43, 2009
120. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G: Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 21: 527-535, 2010
121. Doller A, Gauer S, Sobkowiak E, Geiger H, Pfeilschifter J, Eberhardt W: Angiotensin II induces renal plasminogen activator inhibitor-1 and cyclooxygenase-2 expression post-transcriptionally via activation of the mRNA-stabilizing factor human-antigen R. Am J Pathol 174: 1252-1263, 2009
122. Han SY, Jee YH, Han KH, Kang YS, Kim HK, Han JY, Kim YS, Cha DR: An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy. Nephrol Dial Transplant 21: 2406-2416, 2006 (Pubitemid 44644511)
123. Hao CM, Breyer MD: Physiological regulation of prostaglandins in the kidney. Annu Rev Physiol 70: 357-377, 2008
124. Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, Friedlander G, Terzi F: Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: A new therapeutic approach. Nat Med 11: 867-874, 2005 (Pubitemid 41161119)
125. Wolf G: "As time goes by": Angiotensin II-mediated transactivation of the EGF receptor comes of age. Nephrol Dial Transplant 20: 2050-2053, 2005
126. Norman J, Badie-Dezfooly B, Nord EP, Kurtz I, Schlosser J, Chaudhari A, Fine LG: EGF-induced mitogenesis in proximal tubular cells: Potentiation by angiotensin II. Am J Physiol 253: F299-F2309, 1987
127. Wolf G, Kuncio GS, Sun MJ, Neilson EG: Expression of homeobox genes in a proximal tubular cell line derived from adult mice. Kidney Int 39: 1027-1033, 1991
128. Chen J, Chen JK, Neilson EG, Harris RC: Role of EGF receptor activation in angiotensin II-induced renal epithelial cell hypertrophy. J Am Soc Nephrol 17: 1615-1623, 2006 (Pubitemid 43794664)
129. Castoldi G, di Gioia CR, Travaglini C, Busca G, Redaelli S, Bombardi C, Stella A: Angiotensin II increases tissue-specific inhibitor of metalloproteinase-2 expression in rat aortic smooth muscle cells in vivo: Evidence of a pressure-independent effect. Clin Exp Pharmacol Physiol 34: 205-209, 2007 (Pubitemid 46148263)
130. Daub H, Weiss FU, Wallasch C, Ullrich A: Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379: 557-560, 1996 (Pubitemid 26049585)
131. Murasawa S, Mori Y, Nozawa Y, Gotoh N, Shibuya M, Masaki H, Maruyama K, Tsutsumi Y, Moriguchi Y, Shibazaki Y, Tanaka Y, Iwasaka T, Inada M, Matsubara H: Angiotensin II type 1 receptor-induced extracellular signal-regulated protein kinase activation is mediated by Ca2+/calmodulin-dependent transactivation of epidermal growth factor receptor. Circ Res 82: 1338-1348, 1998 (Pubitemid 28294754)
132. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A: EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402: 884-888, 1999
133. Uchiyama-Tanaka Y, Matsubara H, Mori Y, Kosaki A, Kishimoto N, Amano K, Higashiyama S, Iwasaka T: Involvement of HB-EGF and EGF receptor transactivation in TGF-beta-mediated fibronectin expression in mesangial cells. Kidney Int 62: 799-808, 2002 (Pubitemid 35316709)
134. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP: A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385: 729-733, 1997 (Pubitemid 27098094)
135. Richard DE, Berra E, Pouyssegur J: Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J Biol Chem 275: 26765-26771, 2000
136. Page EL, Robitaille GA, Pouyssegur J, Richard DE: Induction of hypoxia-inducible factor-1alpha by transcriptional and translational mechanisms. J Biol Chem 277: 48403-48409, 2002 (Pubitemid 35470797)
137. Wolf G, Schroeder R, Stahl RA: Angiotensin II induces hypoxia-inducible factor-1 alpha in PC 12 cells through a posttranscriptional mechanism: Role of AT2 receptors. Am J Nephrol 24: 415-421, 2004 (Pubitemid 39279383)
138. Hopfer U, Hopfer H, Jablonski K, Stahl RA, Wolf G: The novel WD-repeat protein Morg1 acts as a molecular scaffold for hypoxia-inducible factor prolyl hydroxylase 3 (PHD3). J Biol Chem 281: 8645-8655, 2006 (Pubitemid 43847969)
139. Hammerschmidt E, Loeffler I, Wolf G: Morg1 heterozygous mice are protected from acute renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 297: F1273-F1287, 2009
140. Kudo Y, Kakinuma Y, Mori Y, Morimoto N, Karashima T, Furihata M, Sato T, Shuin T, Sugiura T: Hypoxia-inducible factor-1alpha is involved in the attenuation of experimentally induced rat glomerulonephritis. Nephron Exp Nephrol 100: e95-e103, 2005 (Pubitemid 40868657)
141. Song YR, You SJ, Lee YM, Chin HJ, Chae DW, Oh YK, Joo KW, Han JS, Na KY: Activation of hypoxia-inducible factor attenuates renal injury in rat remnant kidney. Nephrol Dial Transplant 25: 77-85, 2010
142. Higgins DF, Kimura K, Bernhardt WM, Shrimanker N, Akai Y, Hohenstein B, Saito Y, Johnson RS, Kretzler M, Cohen CD, Eckardt KU, Iwano M, Haase VH: Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest 117: 3810-3820, 2007 (Pubitemid 350224091)
143. Tanaka T, Kato H, Kojima I, Ohse T, Son D, Tawakami T, Yatagawa T, Inagi R, Fujita T, Nangaku M: Hypoxia and expression of hypoxia-inducible factor in the aging kidney. J Gerontol A Biol Sci Med Sci 61: 795-805, 2006 (Pubitemid 44260161)
144. Koitabashi N, Arai M, Niwano K, Watanabe A, Endoh M, Suguta M, Yokoyama T, Tada H, Toyama T, Adachi H, Naito S, Oshima S, Nishida T, Kubota S, Takigawa M, Kurabayashi M: Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure. Eur J Heart Fail 10: 373-379, 2008
145. Nonaka Takahashi S, Fujita T, Takahashi T, Wada Y, Fuke Y, Satomura A, Matsumoto K: TGF-beta1 and CTGF mRNAs are correlated with urinary protein level in IgA nephropathy. J Nephrol 21: 53-63, 2008 (Pubitemid 351780574)
146. Guha M, Xu ZG, Tung D, Lanting L, Natarajan R: Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J 21: 3355-3368, 2007 (Pubitemid 47565554)